Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 3/20 | 0.40 |
| ▸ | PREP | P48147 | 2/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.39 |
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15423475 | 0.89 | HCRTR2 (0.32) | FAPPREPHCRTR2DPP4DPP8 | |
| SCHEMBL25773837 | 0.81 | FAP (0.40) | FAPPREPHCRTR2DPP4DPP8 | |
| SCHEMBL21129420 | 0.77 | HCRTR2 (0.41) | FAPPREPHCRTR2CHRM2CHRM4 | |
| SCHEMBL15423481 | 0.76 | ATM (0.34) | — | |
| SCHEMBL1949667 | 0.75 | CHRM2 (0.39) | FAPPREPCHRM2CHRM4CHRM5 | |
| SCHEMBL28446519 | 0.75 | CHRM2 (0.39) | FAPPREPCHRM2CHRM4CHRM5 | |
| SCHEMBL1725742 | 0.75 | CHRM2 (0.39) | FAPPREPCHRM2CHRM4CHRM5 | |
| SCHEMBL13532952 | 0.75 | FAP (0.42) | FAPPREPHCRTR2DPP4DPP8 | |
| SCHEMBL13218350 | 0.75 | FAP (0.42) | FAPPREPHCRTR2DPP4DPP8 | |
| SCHEMBL8234453 | 0.75 | FAP (0.42) | FAPPREPHCRTR2DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-9655944-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160361375-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2016-12-15 | — | — | US | disclosed |
| US-20160130300-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2016-05-12 | — | — | US | disclosed |
| US-9296782-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2015-06-25 | — | — | US | disclosed |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | FAP 696/4885PREP 1161/4885HCRTR2 4790/4885 |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | FAP 592/4885PREP 1152/4885HCRTR2 4745/4885 |
| US-20160361375-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | FAP 592/4885PREP 1152/4885HCRTR2 4745/4885 |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | FAP 592/4885PREP 1152/4885HCRTR2 4745/4885 |
| US-20160130300-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | FAP 592/4885PREP 1152/4885HCRTR2 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.